About: Robert Motzer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Robert Motzer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	ikertzailea (eu) researcher (en) 연구원 (ko) ricercatore (it) গবেষক (bn) 研究者 (ja) ഗവേഷകൻ (ml) araştırmacı (tr) дослідник (uk) वैज्ञानिक (hi) 研究者 (zh) հետազոտող (hy) hulumtues (sq) onderzoeker (nl)
rdfs:label	Robert Motzer (en) Robert Motzer (es) Robert Motzer (nl) Robert Motzer (sl) Robert Motzer (ast)
skos:prefLabel	Robert Motzer (en) Robert Motzer (es) Robert Motzer (nl) Robert Motzer (sl) Robert Motzer (ast)
name	Robert Motzer (en) Robert Motzer (es) Robert Motzer (nl) Robert Motzer (sl) Robert Motzer (ast)
given name	wds:Q42721742-FAE13073-8FF9-4B10-BFEC-9FBCDABB8FE0
given name	Robert
instance of	wds:Q42721742-90A3E207-A10D-48D8-8A1B-899A64BE6DF9
instance of	Homo sapiens
occupation	wds:Q42721742-69D30146-D51E-478F-8045-5F1131029CE8
employer	wds:Q42721742-016F3B40-F662-4D31-A90A-9E2D85C6A16C
sex or gender	wds:Q42721742-90A57D9F-280E-4AC3-86E1-53E0D90345A0
ISNI	wds:Q42721742-AEB9F1A4-9ED4-43CB-A419-73E084C2D91D
VIAF ID	wds:Q42721742-7E67389D-9913-4F87-A740-F5B70DCE264B
GND ID	wds:Q42721742-830b132a-e25a-49db-9c13-a700b31296fa
Library of Congress authority ID	wds:Q42721742-A549085E-B4EA-4D0A-B81A-F3E69404C79A
date of birth	wds:Q42721742-3A9CDBF8-00F4-4ACC-A244-7A9581E0988C
family name	wds:Q42721742-BD862297-2B43-428A-B07E-3297F9ACBBFE
WorldCat Identities ID (superseded)	wds:Q42721742-78415BF8-E6CF-4572-A2F7-5A8E2BC5E77A
National Library of Israel J9U ID	wds:Q42721742-D3768086-8E77-460B-A8DD-437C896C543E
official website	wds:Q42721742-E5258D36-CBC2-4EDB-88D5-02ABA94FC3AC
VIAF ID	http://viaf.org/viaf/89830268
GND ID	https://d-nb.info/gnd/1017477523
Library of Congress authority ID	http://id.loc.gov/authorities/names/n2003129779
occupation	researcher
employer	Memorial Sloan Kettering Cancer Center
sex or gender	male
ISNI	0000000081632026
VIAF ID	89830268
GND ID	1017477523
Library of Congress authority ID	n2003129779
date of birth	1950-01-01 00:00:00Z (xsd:dateTime)
family name	Motzer
WorldCat Identities ID (superseded)	lccn-n2003129779
National Library of Israel J9U ID	987007360168605171
official website	https://synapse.mskcc.org/synapse/people/1694
ORCID iD	wds:Q42721742-0F1BCA8C-BB09-4372-80ED-B7A9164D5658
ORCID iD	https://orcid.org/0000-0001-6925-2327
ORCID iD	0000-0001-6925-2327
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q42721742
is author of	Immunohistochemical Expression of Hypoxia Inducible Factor-1α and its Downstream Molecules in Sarcomatoid Renal Cell Carcinoma Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Targeted drugs for metastatic renal cell carcinoma The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. Chemotherapy for teratoma with malignant transformation. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma NCCN clinical practice guidelines in oncology: kidney cancer Overall survival in renal-cell carcinoma with pazopanib versus sunitinib Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Sunitinib versus interferon alfa in metastatic renal-cell carcinoma Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Kidney cancer, version 3.2015. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. A POSTOPERATIVE PROGNOSTIC NOMOGRAM PREDICTING RECURRENCE FOR PATIENTS WITH CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma A postoperative prognostic nomogram for renal cell carcinoma Targeting von Hippel-Lindau pathway in renal cell carcinoma Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors: A 28-Year Experience at Memorial Sloan-Kettering Cancer Center Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software